Katherine A Lyseng-Williamson

Summary

Affiliation: Adis International Limited
Country: New Zealand

Publications

  1. ncbi request reprint Cerivastatin
    K J McClellan
    Adis International Limited, Auckland, New Zealand
    Drugs 55:415-20; discussion 421-2. 1998
  2. ncbi request reprint Glimepiride. A review of its use in the management of type 2 diabetes mellitus
    H D Langtry
    Adis International Limited, Auckland, New Zealand
    Drugs 55:563-84. 1998
  3. ncbi request reprint Fludarabine. An update of its pharmacology and use in the treatment of haematological malignancies
    J C Adkins
    Adis International Limited, Auckland, New Zealand
    Drugs 53:1005-37. 1997
  4. ncbi request reprint Milnacipran. A review of its use in depression
    C M Spencer
    Adis International Limited, Auckland, New Zealand
    Drugs 56:405-27. 1998
  5. doi request reprint Telmisartan/amlodipine: single-pill combination in hypertension
    Marit D Moen
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    Am J Cardiovasc Drugs 10:401-12. 2010
  6. ncbi request reprint Quinapril: a further update of its pharmacology and therapeutic use in cardiovascular disorders
    Christine R Culy
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    Drugs 62:339-85. 2002
  7. doi request reprint Hyaluronic acid (Supartz®): a review of its use in osteoarthritis of the knee
    Monique P Curran
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    Drugs Aging 27:925-41. 2010
  8. doi request reprint Sitagliptin: a review of its use in the management of type 2 diabetes mellitus
    Sohita Dhillon
    Adis, Auckland, New Zealand
    Drugs 70:489-512. 2010
  9. ncbi request reprint Risedronate
    K L Goa
    Adis International Limited, Auckland, New Zealand
    Drugs Aging 13:83-91; discussion 92. 1998
  10. doi request reprint Atazanavir: in pediatric patients with HIV-1 infection
    Emma D Deeks
    Adis, Auckland, New Zealand
    Paediatr Drugs 14:131-41. 2012

Collaborators

Detail Information

Publications1188 found, 100 shown here

  1. ncbi request reprint Cerivastatin
    K J McClellan
    Adis International Limited, Auckland, New Zealand
    Drugs 55:415-20; discussion 421-2. 1998
    ..No drug interactions were observed when cerivastatin was coadministered with digoxin, warfarin, cimetidine or the antacid magnesium/aluminium hydroxide...
  2. ncbi request reprint Glimepiride. A review of its use in the management of type 2 diabetes mellitus
    H D Langtry
    Adis International Limited, Auckland, New Zealand
    Drugs 55:563-84. 1998
    ..Dosage is usually started at 1 mg/day, titrated to glycaemic control at 1- to 2-week intervals to a usual dosage range of 1 to 4 mg/day (maximum 6 mg/day in the UK or 8 mg/day in the US)...
  3. ncbi request reprint Fludarabine. An update of its pharmacology and use in the treatment of haematological malignancies
    J C Adkins
    Adis International Limited, Auckland, New Zealand
    Drugs 53:1005-37. 1997
    ....
  4. ncbi request reprint Milnacipran. A review of its use in depression
    C M Spencer
    Adis International Limited, Auckland, New Zealand
    Drugs 56:405-27. 1998
    ..However, dysuria has been reported in 7% of male patients receiving milnacipran...
  5. doi request reprint Telmisartan/amlodipine: single-pill combination in hypertension
    Marit D Moen
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    Am J Cardiovasc Drugs 10:401-12. 2010
    ..Telmisartan/amlodipine was generally well tolerated in clinical trials, including two 36-week follow-up studies...
  6. ncbi request reprint Quinapril: a further update of its pharmacology and therapeutic use in cardiovascular disorders
    Christine R Culy
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    Drugs 62:339-85. 2002
    ..3% and hypotension occurred in <1 and 2.9% of quinapril recipients with hypertension or congestive heart failure, respectively. No increase in adverse events was observed when the dosage was increased from 10 to 40 mg/day...
  7. doi request reprint Hyaluronic acid (Supartz®): a review of its use in osteoarthritis of the knee
    Monique P Curran
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    Drugs Aging 27:925-41. 2010
    ..The most common adverse events reported in Supartz® recipients were arthralgia, arthropathy/arthrosis/arthritis, back pain, nonspecific pain, injection-site reaction, headache and injection-site pain...
  8. doi request reprint Sitagliptin: a review of its use in the management of type 2 diabetes mellitus
    Sohita Dhillon
    Adis, Auckland, New Zealand
    Drugs 70:489-512. 2010
    ....
  9. ncbi request reprint Risedronate
    K L Goa
    Adis International Limited, Auckland, New Zealand
    Drugs Aging 13:83-91; discussion 92. 1998
    ..The incidence of gastrointestinal or other adverse events was similar in patients treated with risedronate or placebo in clinical trials...
  10. doi request reprint Atazanavir: in pediatric patients with HIV-1 infection
    Emma D Deeks
    Adis, Auckland, New Zealand
    Paediatr Drugs 14:131-41. 2012
    ..In the PACTG 1020A trial, use of atazanavir (with or without ritonavir) in pediatric patients aged 6 to <18 years was associated with a similar safety profile to that reported in adults...
  11. doi request reprint Silodosin in the treatment of the signs and symptoms of benign prostatic hyperplasia: profile report
    Monique P Curran
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    Drugs Aging 28:843-5. 2011
  12. ncbi request reprint Alendronate. A review of its pharmacological properties and therapeutic efficacy in postmenopausal osteoporosis
    W Jeal
    Adis International Limited, Auckland, New Zealand
    Drugs 53:415-34. 1997
    ..Thus, alendronate, with its demonstrated beneficial effects and its good tolerability profile (when taken as recommended), is a promising alternative treatment option for the management of postmenopausal osteoporosis...
  13. doi request reprint Methylphenidate transdermal system: in attention-deficit hyperactivity disorder in adolescents
    Gillian M Keating
    Adis, a Wolters Kluwer Business, Auckland, NZ
    CNS Drugs 25:333-42. 2011
    ..The vast majority of treatment-emergent adverse events were of mild to moderate severity in both the short-term core trial and the longer-term extension study...
  14. ncbi request reprint Ethinylestradiol/chlormadinone acetate
    Monique P Curran
    Adis International Limited, 41 Centorian Drive, PB 65901, Mairangi Bay, Auckland, New Zealand
    Drugs 64:751-60; discussion 761-2. 2004
    ..Adverse events were those commonly reported with oral contraceptives. As expected, the most common menstrual disturbances were breakthrough bleeding, spotting and amenorrhoea...
  15. ncbi request reprint Gatifloxacin: a review of its use in the treatment of bacterial infections in the US
    Susan J Keam
    Adis International Limited, Auckland, New Zealand
    Drugs 65:695-724. 2005
    ....
  16. ncbi request reprint Tegaserod: a review of its use in the management of irritable bowel syndrome with constipation in women
    Antona J Wagstaff
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    Drugs 63:1101-20. 2003
    ....
  17. ncbi request reprint Rotigotine: in Parkinson's disease
    Neil A Reynolds
    Adis International Limited, Auckland, New Zealand
    CNS Drugs 19:973-81. 2005
    ..Rotigotine was generally well tolerated in clinical trials as both monotherapy and when administered with levodopa; adverse events were generally mild or moderate in severity...
  18. ncbi request reprint Selegiline transdermal system: in the treatment of major depressive disorder
    James E Frampton
    Wolters Kluwer Health, Adis, Auckland, New Zealand
    Drugs 67:257-65; discussion 266-7. 2007
    ..The incidence of sexual adverse effects and weight gain was low and similar to that with placebo...
  19. ncbi request reprint Zanamivir: an update of its use in influenza
    Susan M Cheer
    Adis International Limited, Auckland, New Zealand
    Drugs 62:71-106. 2002
    ....
  20. ncbi request reprint Recombinant hepatitis B vaccine (Engerix-B): a review of its immunogenicity and protective efficacy against hepatitis B
    Gillian M Keating
    Adis International Limited, Auckland, New Zealand
    Drugs 63:1021-51. 2003
    ..In addition, it appears that Hep-B(Eng) confers immunity for at least 10 years. Hep-B(Eng) has an important role in mass vaccination campaigns against hepatitis B, as well as in groups considered at high risk of acquiring hepatitis B...
  21. ncbi request reprint Ambrisentan
    Jamie D Croxtall
    Wolters Kluwer Health Adis, Auckland, New Zealand
    Drugs 68:2195-204. 2008
    ..One-year survival rates with ambrisentan were 95-97%. Treatment with ambrisentan for up to 2.8 years was generally well tolerated in clinical trials...
  22. ncbi request reprint Piperacillin/tazobactam: an updated review of its use in the treatment of bacterial infections
    C M Perry
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    Drugs 57:805-43. 1999
    ..The incidence of adverse events with piperacillin/tazobactam is higher when the combination is given in combination with an aminoglycoside than when given as monotherapy...
  23. ncbi request reprint Valaciclovir: a review of its long term utility in the management of genital herpes simplex virus and cytomegalovirus infections
    D Ormrod
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    Drugs 59:839-63. 2000
    ..While the clinical benefits of valaciclovir in some immunocompromised patients may outweigh the risk of TMA, close monitoring for symptoms of TMA is indicated in all immunocompromised patients receiving high-dose valaciclovir...
  24. ncbi request reprint Pramipexole: in restless legs syndrome
    Paul L McCormack
    Wolters Kluwer Health Adis, Auckland, New Zealand
    CNS Drugs 21:429-37; discussion 438-40. 2007
    ..Pramipexole was generally well tolerated, with most adverse events being transient and of mild to moderate severity...
  25. doi request reprint Indacaterol: a review of its use as maintenance therapy in patients with chronic obstructive pulmonary disease
    Kate McKeage
    Adis, Auckland, New Zealand
    Drugs 72:543-63. 2012
    ..In conclusion, indacaterol provides a valuable option for the maintenance treatment of adults with COPD...
  26. doi request reprint Darunavir: in treatment-experienced pediatric patients with HIV-1 infection
    Kate McKeage
    Adis, a Wolters Kluwer Business, North Shore 0754, Auckland, New Zealand
    Paediatr Drugs 12:123-31. 2010
    ..The mean triglyceride level at week 48 was lower than that at baseline, and cholesterol levels increased slightly but remained within the normal range...
  27. ncbi request reprint Lisinopril. A review of its pharmacology and use in the management of the complications of diabetes mellitus
    K L Goa
    Adis International Limited, Auckland, New Zealand
    Drugs 53:1081-105. 1997
    ..These findings, together with some evidence for an effect of lisinopril in delaying progression of retinopathy and in reducing mortality, suggest a broader role for the drug in managing diabetic vascular complications...
  28. ncbi request reprint Adalimumab: in psoriatic arthritis
    Dene Simpson
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    Drugs 66:1487-96; discussion 1497-9. 2006
    ..001). Adalimumab was generally well-tolerated in clinical trials of psoriatic arthritis; the adverse event profile appears to be similar to that associated with use of the drug in rheumatoid arthritis...
  29. ncbi request reprint Lopinavir
    M Hurst
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    Drugs 60:1371-9; discussion 1380-1. 2000
    ..Diarrhoea, nausea and asthenia were the most frequently reported adverse effects in patients receiving lopinavir/ritonavir-based regimens. Elevated total cholesterol, triglyceride and hepatic enzyme levels were also reported...
  30. ncbi request reprint Dienogest
    R H Foster
    Adis International Limited, Auckland, New Zealand
    Drugs 56:825-33; discussion 834-5. 1998
    ..The drug does not produce androgenic adverse effects and has little clinically significant effect on metabolic, lipid and haemostatic parameters...
  31. ncbi request reprint Rofecoxib
    L J Scott
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    Drugs 58:499-505; discussion 506-7. 1999
    ..5, 25 or 50 mg/day than in those receiving ibuprofen, diclofenac or nabumetone...
  32. ncbi request reprint Diphtheria-tetanus-acellular pertussis vaccine adsorbed (Triacelluvax; DTaP3-CB): a review of its use in the prevention of Bordetella pertussis infection
    A J Matheson
    Adis International Limited, Auckland, New Zealand
    Paediatr Drugs 2:139-59. 2000
    ..Concomitant administration of DTaP3-CB with hepatitis B, oral polio or Haemophilus influenzae type B vaccines did not affect the immunogenicity of these other paediatric vaccines...
  33. ncbi request reprint Panipenem/betamipron
    Karen L Goa
    Adis International Limited, Auckland, New Zealand
    Drugs 63:913-25; discussion 926. 2003
    ..Panipenem/betamipron is well tolerated with few adverse events reported in clinical trials, most commonly elevated serum levels of hepatic transaminases and eosinophils, rash and diarrhoea...
  34. ncbi request reprint Mycophenolate sodium delayed release: prevention of renal transplant rejection
    Monique P Curran
    Adis International Limited, Auckland, New Zealand
    Drugs 65:799-805; discussion 806-7. 2005
    ..The incidence of gastrointestinal adverse events with mycophenolate sodium delayed release was similar to that with mycophenolate mofetil...
  35. ncbi request reprint Valganciclovir: a review of its use in the management of CMV infection and disease in immunocompromised patients
    Risto S Cvetkovic
    Adis International Limited, Auckland, New Zealand
    Drugs 65:859-78. 2005
    ....
  36. ncbi request reprint Atovaquone/proguanil: a review of its use for the prophylaxis of Plasmodium falciparum malaria
    Kate McKeage
    Adis International Limited, Auckland, New Zealand
    Drugs 63:597-623. 2003
    ..Significantly fewer recipients of atovaquone/proguanil discontinued treatment because of adverse events than individuals receiving chloroquine plus proguanil or mefloquine (p < 0.05)...
  37. ncbi request reprint Acamprosate. A review of its pharmacology and clinical potential in the management of alcohol dependence after detoxification
    M I Wilde
    Adis International Ltd, Aucklund, New Zealand
    Drugs 53:1038-53. 1997
    ..Longer term and comparative trials with other active therapies are required to confirm these promising results...
  38. ncbi request reprint Rasagiline
    M Asif A Siddiqui
    Adis International Limited, Auckland 1311, New Zealand
    Drugs Aging 22:83-91; discussion 93-4. 2005
    ..Adverse events with rasagiline were generally similar in frequency to those seen in placebo or entacapone recipients...
  39. ncbi request reprint Bevacizumab: in first-line treatment of metastatic breast cancer
    Lesley J Scott
    Wolters Kluwer Health Adis, Auckland, New Zealand, an editorial office of Wolters Kluwer Health, Conshohocken, Pennsylvania, USA
    Drugs 67:1793-9. 2007
    ....
  40. ncbi request reprint Brinzolamide : a review of its use in the management of primary open-angle glaucoma and ocular hypertension
    Risto S Cvetkovic
    Adis International Limited, Auckland, New Zealand
    Drugs Aging 20:919-47. 2003
    ..Brinzolamide 1% administered twice daily is among the least costly alternatives and adjuncts to beta-blocker therapy for glaucoma and is generally associated with less direct medical cost than dorzolamide...
  41. ncbi request reprint Zoledronic acid: a pharmacoeconomic review of its use in the management of bone metastases
    Kate McKeage
    Wolters Kluwer Health Adis, Auckland, New Zealand
    Pharmacoeconomics 26:251-68. 2008
    ....
  42. doi request reprint DTaP(5)-IPV-Hib vaccine (Pediacel®)
    James E Frampton
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    Paediatr Drugs 13:401-15. 2011
    ..It had an adverse event profile generally similar to that of other combination vaccines based on diphtheria, tetanus and acellular pertussis vaccine, including Infanrix®-IPV+Hib and Infanrix® hexa...
  43. doi request reprint Rituximab: as first-line maintenance therapy following rituximab-containing therapy for follicular lymphoma
    Jamie D Croxtall
    Adis, a Wolters Kluwer Business, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore 0754, Auckland, New Zealand
    Drugs 71:885-95. 2011
    ..Rituximab had an acceptable tolerability profile as single-agent maintenance therapy in patients with follicular lymphoma with no new or unexpected adverse events compared with induction therapy...
  44. ncbi request reprint Pamidronate. A review of its use in the management of osteolytic bone metastases, tumour-induced hypercalcaemia and Paget's disease of bone
    A J Coukell
    Adis International Limited, Auckland, New Zealand
    Drugs Aging 12:149-68. 1998
    ..It is an effective treatment for Paget's disease and is the treatment of choice where oral bisphosphonates are not an option...
  45. ncbi request reprint Ofloxacin otic solution: a review of its use in the management of ear infections
    K L Simpson
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    Drugs 58:509-31. 1999
    ..Unlike comparative ototopical antibacterials, ofloxacin was not ototoxic or chondrotoxic in animal studies. In addition, no ototoxicity was detected in clinical studies in humans...
  46. ncbi request reprint Transdermal oxybutynin: for overactive bladder
    Lynne M Bang
    Adis International Limited, Auckland, New Zealand
    Drugs Aging 20:857-64. 2003
    ..Adverse events associated with anticholinergic drugs (e.g. dry mouth) were less frequently reported in patients treated with transdermal oxybutynin than in those receiving orally administered oxybutynin or tolterodine...
  47. ncbi request reprint Capecitabine: in advanced gastric or oesophagogastric cancer
    Sohita Dhillon
    Wolters Kluwer Health Adis, Auckland, New Zealand, an editorial office of Wolters Kluwer Health, Conshohocken, Pennsylvania, USA
    Drugs 67:601-10. 2007
    ....
  48. doi request reprint Esmolol: a review of its use in the short-term treatment of tachyarrhythmias and the short-term control of tachycardia and hypertension
    Karly P Garnock-Jones
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    Drugs 72:109-32. 2012
    ..Despite this, esmolol, as a fast-acting, rapidly reversible, easily titratable β-blocker, is an established option for the short-term treatment of tachyarrhythmias and the short-term control of tachycardia and hypertension...
  49. ncbi request reprint Cefotaxime. A reappraisal of its antibacterial activity and pharmacokinetic properties, and a review of its therapeutic efficacy when administered twice daily for the treatment of mild to moderate infections
    R N Brogden
    Adis International Limited, Auckland, New Zealand
    Drugs 53:483-510. 1997
    ..When appropriately administered twice daily there is potential to lower the cost of antibacterial treatment without compromising efficacy...
  50. ncbi request reprint Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections
    H M Lamb
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    Drugs 58:1061-97. 1999
    ..3% of recipients of comparator agents. Quinupristin/dalfopristin inhibits cytochrome P450 3A4 and therefore has the potential to increase the plasma concentrations of substrates of this enzyme...
  51. ncbi request reprint Rivastigmine transdermal patch: in the treatment of dementia of the Alzheimer's type
    Lily P H Yang
    Wolters Kluwer Health 1 Adis, Auckland, New Zealand
    CNS Drugs 21:957-65. 2007
  52. doi request reprint Sunitinib: in advanced, well differentiated pancreatic neuroendocrine tumors
    Emma D Deeks
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    BioDrugs 25:307-16. 2011
    ....
  53. ncbi request reprint Levocetirizine: a review of its use in the management of allergic rhinitis and skin allergies
    Philip I Hair
    Adis International Limited, 51 Centorian Drive, Mairangi Bay, Auckland 1311, New Zealand
    Drugs 66:973-96. 2006
    ..Overall, levocetirizine is a valuable addition to the oral H(1) receptor antagonists available for the treatment of allergic rhinitis and as first-line therapy in patients with CIU...
  54. ncbi request reprint Barnidipine
    H S Malhotra
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    Drugs 61:989-96; discussion 997-8. 2001
    ..Oedema is less frequent than with amlodipine and nitrendipine. Its use is not associated with reflex tachycardia...
  55. ncbi request reprint Telmisartan: a review of its use in hypertension
    M Sharpe
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    Drugs 61:1501-29. 2001
    ..Telmisartan was well tolerated in patients with mild to moderate hypertension and was significantly less likely to cause persistent, dry cough than lisinopril...
  56. ncbi request reprint Inhaled salmeterol/fluticasone propionate combination: a pharmacoeconomic review of its use in the management of asthma
    Katherine A Lyseng-Williamson
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    Pharmacoeconomics 21:951-89. 2003
    ....
  57. doi request reprint Methylnaltrexone
    Karly P Garnock-Jones
    Adis, Wolters Kluwer Business, Auckland, New Zealand
    Drugs 70:919-28. 2010
    ..Methylnaltrexone was generally well tolerated in clinical trials; most adverse events were of mild to moderate severity...
  58. doi request reprint Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma
    Gillian M Keating
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    Drugs 70:1445-76. 2010
    ..In conclusion, rituximab remains a valuable therapy in patients with CLL, low-grade or follicular lymphoma and diffuse large B-cell lymphoma and, in a variety of treatment settings, represents the standard of care...
  59. ncbi request reprint Miglitol: a review of its therapeutic potential in type 2 diabetes mellitus
    L J Scott
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    Drugs 59:521-49. 2000
    ..No dosage adjustments are required in elderly patients, in those with hepatic impairment or in those with mild to moderate renal insufficiency...
  60. ncbi request reprint Amisulpride: a review of its use in the management of schizophrenia
    M P Curran
    Adis International Limited, Auckland, New Zealand
    Drugs 61:2123-50. 2001
    ..At low dosages of amisulpride (< or =300 mg/day), the incidence of adverse events (including extrapyramidal symptoms) reported with amisulpride was similar to that with placebo...
  61. ncbi request reprint Losartan: a review of its use in stroke risk reduction in patients with hypertension and left ventricular hypertrophy
    Marit D Moen
    Adis International Limited, Auckland, New Zealand
    Drugs 65:2657-74. 2005
    ....
  62. ncbi request reprint Moxonidine: a review of its use in essential hypertension
    Caroline Fenton
    Adis International Limited, Auckland, New Zealand
    Drugs 66:477-96. 2006
    ..Thus, moxonidine is a good option in the treatment of patients with mild to moderate hypertension, particularly as adjunctive therapy in patients with the metabolic syndrome...
  63. ncbi request reprint Recombinant full-length parathyroid hormone (1-84)
    Marit D Moen
    Wolters Kluwer Health Adis, Auckland, New Zealand
    Drugs 66:2371-81; discussion 2382-5. 2006
    ..PTH(1-84) is generally well tolerated, although patients should be monitored for elevated serum calcium...
  64. ncbi request reprint Deferasirox : a review of its use in the management of transfusional chronic iron overload
    Lily P H Yang
    Wolters Kluwer Health Adis, Auckland, New Zealand
    Drugs 67:2211-30. 2007
    ....
  65. ncbi request reprint Topiramate. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of epilepsy
    H D Langtry
    Adis International Limited, Auckland, New Zealand
    Drugs 54:752-73. 1997
    ..Thus, topiramate can be considered an important new drug for the management of patients with refractory epilepsy...
  66. ncbi request reprint Diclofenac/misoprostol. Pharmacoeconomic implications of therapy
    G L Plosker
    Adis International Limited, Auckland, New Zealand
    Pharmacoeconomics 16:85-98. 1999
    ....
  67. ncbi request reprint Metoprolol: a review of its use in chronic heart failure
    A Prakash
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    Drugs 60:647-78. 2000
    ..The drug is well tolerated when treatment is initiated in low dosages and gradually increased at intervals of 1 to 2 weeks...
  68. ncbi request reprint Alvimopan
    Monique P Curran
    Wolters Kluwer Health Adis, Auckland, New Zealand
    Drugs 68:2011-9. 2008
    ..Alvimopan did not reduce opioid-induced analgesia and/or increase the amount of opioids administered postoperatively. Short-term alvimopan was generally well tolerated in adults undergoing bowel resection...
  69. ncbi request reprint Gemifloxacin
    M N Lowe
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    Drugs 59:1137-47; discussion 1148. 2000
    ..Gemifloxacin has a low potential for mild phototoxicity (comparable to that of ciprofloxacin)...
  70. ncbi request reprint Reduced-antigen, combined diphtheria-tetanus-acellular pertussis vaccine, adsorbed (Boostrix) US formulation): use as a single-dose booster immunization in adolescents aged 10-18 years
    James E Frampton
    Adis International Inc, Yardley, PA 19067, USA
    Paediatr Drugs 8:189-95; discussion 196. 2006
    ....
  71. doi request reprint Belimumab: in systemic lupus erythematosus
    Celeste B Burness
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    Drugs 71:2435-44. 2011
    ..There were no meaningful differences between the incidence of serious infections and malignancies with belimumab or placebo...
  72. ncbi request reprint Estradiol and dydrogesterone. A review of their combined use as hormone replacement therapy in postmenopausal women
    R H Foster
    Adis International Limited, Auckland, New Zealand
    Drugs Aging 11:309-32. 1997
    ..Comparisons with other standard HRT regimens and long term data (including clinical end-points) are needed. In the meantime, this regimen can be regarded as an acceptable HRT option...
  73. ncbi request reprint Zolmitriptan: a review of its use in migraine
    C M Spencer
    Adis International Limited, Auckland, New Zealand
    Drugs 58:347-74. 1999
    ..The most common adverse events with zolmitriptan therapy are asthenia, heaviness other than that of the chest or neck, dry mouth, nausea, dizziness, somnolence, paraesthesia, warm sensation, tightness, vasodilation and chest pain...
  74. ncbi request reprint Spotlight on insulin aspart in type 1 and 2 diabetes mellitus
    Therese M Chapman
    Adis International Inc, Langhorne, Pennsylvania 19047, USA
    Treat Endocrinol 2:71-6. 2003
    ..Moreover, insulin aspart tended to be associated with a lower occurrence of nocturnal hypoglycemia and severe hypoglycemic events than regular human insulin...
  75. doi request reprint Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents
    Karly P Garnock-Jones
    Wolters Kluwer Health mid R Adis, Auckland, New Zealand, an editorial office of Wolters Kluwer Health, Philadelphia, Pennsylvania, USA
    Paediatr Drugs 11:203-26. 2009
    ....
  76. ncbi request reprint Spotlight on agalsidase beta in Fabry disease
    Gillian M Keating
    Wolters Kluwer Health Adis, Auckland, New Zealand
    BioDrugs 21:269-71. 2007
    ..Thus, agalsidase beta represents an important advance in the treatment of Fabry disease, and agalsidase beta therapy should be strongly considered in patients with Fabry disease who are suitable candidates...
  77. ncbi request reprint Desloratadine
    K McClellan
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    Drugs 61:789-96; discussion 797. 2001
    ..Sleep and daytime performance also improved. Desloratadine was well tolerated in clinical trials and had an adverse event profile similar to that of placebo in patients with SAR (with or without asthma) or CIU...
  78. ncbi request reprint Imatinib: a review of its use in the management of gastrointestinal stromal tumours
    M Asif A Siddiqui
    Wolters Kluwer Health Adis, Auckland, New Zealand
    Drugs 67:805-20. 2007
    ..Further data are required to evaluate the use of imatinib in adjuvant and neoadjuvant settings. Nevertheless, imatinib currently provides the most effective treatment option in the management of advanced GIST...
  79. ncbi request reprint Perindopril: an updated review of its use in hypertension
    M Hurst
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    Drugs 61:867-96. 2001
    ..Perindopril has a similar adverse event profile to that of other ACE inhibitors; cough is the most common event reported during treatment, and is also the most common adverse event responsible for treatment withdrawal...
  80. ncbi request reprint Spotlight on glatiramer acetate in relapsing-remitting multiple sclerosis
    Dene Simpson
    Adis International Limited, 41 Centorian Drive, PB 65901, Mairangi Bay, Auckland 10, New Zealand
    BioDrugs 17:207-10. 2003
    ..Based on available data and current management guidelines, glatiramer acetate is a valuable first-line treatment option for patients with RRMS...
  81. doi request reprint Teriparatide: a review of its use in osteoporosis
    Stephanie K A Blick
    Wolters Kluwer Health, Adis, Auckland, New Zealand
    Drugs 68:2709-37. 2008
    ....
  82. doi request reprint Naproxen/esomeprazole fixed-dose combination: for the treatment of arthritic symptoms and to reduce the risk of gastric ulcers
    Sohita Dhillon
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    Drugs Aging 28:237-48. 2011
    ..The fixed-dose combination was generally well tolerated in these studies, with an upper gastrointestinal tolerability profile generally better than that of naproxen and similar to that of celecoxib...
  83. ncbi request reprint Desmopressin: in adults with nocturia
    Risto S Cvetkovic
    Adis International Limited, Auckland, New Zealand
    Drugs 65:99-107; discussion 108-9. 2005
    ..Most desmopressin-related adverse events were transient and mild or moderate in severity. Clinically significant hyponatraemia was reported in approximately 5% and required withdrawal from studies in < or =3% of patients...
  84. ncbi request reprint Lubiprostone
    Kate McKeage
    Adis International Limited, 41 Centorian Drive, Mairangi Bay, Auckland 1311, New Zealand
    Drugs 66:873-9. 2006
    ..Nausea was the most common adverse event, occurring in up to 31% of patients receiving lubiprostone...
  85. ncbi request reprint Etanercept: a review of its use in the management of ankylosing spondylitis and psoriatic arthritis
    Sheridan M Hoy
    Wolters Kluwer Health Adis, Auckland, New Zealand, an editorial office of Wolters Kluwer Health, Conshohocken, Pennsylvania, USA
    Drugs 67:2609-33. 2007
    ..In the meantime, etanercept is a valuable treatment option for patients with ankylosing spondylitis or psoriatic arthritis who are suitable candidates for therapy...
  86. doi request reprint Colesevelam: in pediatric patients with heterozygous familial hypercholesterolemia
    Caroline M Perry
    Adis, a Wolters Kluwer Business, North Shore 0754, Auckland, New Zealand
    Paediatr Drugs 12:133-40. 2010
    ..75 g/day. Colesevelam 3.75 g/day was generally well tolerated for up to 26 weeks by pediatric patients with heterozygous familial hypercholesterolemia...
  87. doi request reprint Strontium ranelate: a review of its use in the treatment of postmenopausal osteoporosis
    Emma D Deeks
    Adis, Auckland, New Zealand
    Drugs 70:733-59. 2010
    ..Overall, the clinical data available suggest that strontium ranelate is an effective and generally well tolerated option for the first-line treatment of postmenopausal osteoporosis...
  88. doi request reprint Lenalidomide: a review of its use in the treatment of relapsed or refractory multiple myeloma
    Lesley J Scott
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    Drugs 71:625-49. 2011
    ..Thus, combination therapy with lenalidomide plus dexamethasone provides a valuable option for the treatment of relapsed or refractory adult patients with multiple myeloma...
  89. ncbi request reprint Beclometasone dipropionate/formoterol: in an HFA-propelled pressurised metered-dose inhaler
    Sohita Dhillon
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    Drugs 66:1475-83; discussion 1484-5. 2006
    ..Moreover, a single high dose of BDP/formoterol (1000 microg/60 microg) was generally well tolerated in patients with asthma...
  90. doi request reprint Fesoterodine
    Kate McKeage
    Wolters Kluwer Health mid R Adis, Auckland, New Zealand, an editorial office of Wolters Kluwer Health, Philadelphia, Pennsylvania, USA
    Drugs 69:731-8. 2009
    ..black triangle Fesoterodine 4 or 8 mg once daily was generally well tolerated in patients with OAB; the most frequent adverse event was dry mouth, which was generally mild to moderate in severity...
  91. doi request reprint Rosuvastatin: a review of its use in the prevention of cardiovascular disease in apparently healthy women or men with normal LDL-C levels and elevated hsCRP levels
    Natalie J Carter
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    Am J Cardiovasc Drugs 10:383-400. 2010
    ....
  92. doi request reprint Saxagliptin: a review of its use as combination therapy in the management of type 2 diabetes mellitus in the EU
    Lily P H Yang
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    Drugs 72:229-48. 2012
    ..In conclusion, saxagliptin is a useful option as add-on therapy to metformin, a sulfonylurea, a thiazolidinedione, or insulin (with or without metformin) in patients with type 2 diabetes who require combination therapy...
  93. doi request reprint Quetiapine: a pharmacoeconomic review of its use in bipolar disorder
    Greg L Plosker
    Adis, Auckland, New Zealand
    Pharmacoeconomics 30:611-31. 2012
    ....
  94. ncbi request reprint Glipizide. A review of the pharmacoeconomic implications of the extended-release formulation in type 2 diabetes mellitus
    R H Foster
    Adis International Limited, Auckland, New Zealand
    Pharmacoeconomics 18:289-306. 2000
    ....
  95. ncbi request reprint Lansoprazole: an update of its place in the management of acid-related disorders
    A J Matheson
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    Drugs 61:1801-33. 2001
    ..Lansoprazole has emerged as a useful and well tolerated treatment option in the management of acid-related disorders...
  96. ncbi request reprint Extended-release methylphenidate (Ritalin LA)
    Katherine A Lyseng-Williamson
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    Drugs 62:2251-9; discussion 2260-1. 2002
    ..In clinical trials, the safety and tolerability profiles of extended-release methylphenidate were consistent with that of the immediate-release formulation...
  97. ncbi request reprint Ciprofloxacin extended release: in the treatment of urinary tract infections and uncomplicated pyelonephritis
    John Waugh
    Adis International Limited, Auckland, New Zealand
    Drugs Aging 21:55-64; discussion 65-6. 2004
    ..black triangle Ciprofloxacin XR was generally well tolerated in patients with uncomplicated or complicated UTIs or acute uncomplicated pyelonephritis and showed similar tolerability to that of the immediate-release formulation...
  98. ncbi request reprint Spotlight on verteporfin in subfoveal choroidal neovascularisation
    Susan J Keam
    Adis International Limited, Auckland, New Zealand
    Drugs Aging 21:203-9. 2004
    ..Approximately 5% of patients with occult with no classic subfoveal CNV secondary to AMD reported severe vision decrease within 7 days of treatment in clinical trials; 3 months later, several patients had recovered some of this loss...
  99. ncbi request reprint Sumatriptan fast-disintegrating/rapid-release tablets
    Marit D Moen
    Adis International Limited, 41 Centorian Drive, Mairangi Bay, Auckland 1311, New Zealand
    Drugs 66:883-90. 2006
    ..Sumatriptan FDT/RRT tablets were generally well tolerated; the tolerability profile was similar to that reported for standard sumatriptan tablets in other studies...
  100. ncbi request reprint Trastuzumab: a pharmacoeconomic review of its use in early breast cancer
    Kate McKeage
    Wolters Kluwer Health Adis, Auckland, New Zealand
    Pharmacoeconomics 26:699-719. 2008
    ..Available pharmacoeconomic data from several countries, despite some inherent limitations, support the use of adjuvant trastuzumab for 1 year as a cost-effective treatment relative to chemotherapy alone in this patient population...
  101. doi request reprint Caspofungin: in pediatric patients with fungal infections
    Karly P Garnock-Jones
    Wolters Kluwer Health mid R Adis, Auckland, New Zealand, an editorial office of Wolters Kluwer Health, Philadelphia, Pennsylvania, USA
    Paediatr Drugs 11:259-69. 2009
    ..Few caspofungin recipients reported serious drug-related adverse events or discontinued treatment as a result of drug-related adverse events...